Early Phase 1
Completed N=19
CRF - Nociceptin Receptor Interactions
Healthy
Source: ClinicalTrials.gov NCT03302416 ↗
Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcomePrimary: [C-11]NOP-1A Volume of Distribution Expressed Relative to Total Plasma Concentration — 16.3; 18.7; 11.6; 13.3 mL/cm^3 — p=0.005
Summary
To determine if [C-11]NOP-1A receptor binding (VT) can be altered by an intravenous hydrocortisone (cortisol) challenge through CRF-NOP interactions
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY [C-11]NOP-1A Volume of Distribution Expressed Relative to Total Plasma Concentration |
16.3; 18.7; 11.6; 13.3; 9.4; 10.6 | 0.005 sig |
Eligibility Criteria
Inclusion Criteria
- Males or females between 18 and 40 years old
Exclusion Criteria
- Current DSM-5 psychiatric disorders
- Binge drinking as defined in NIAAA criteria in the past month
- Recreational abuse of opiates, sedative-hypnotics, cocaine, amphetamines, MDMA, and PCP, as well as cannabis use
- Currently on any prescription medical or psychotropic medication;
- Current or past severe medical, endocrine, cardiovascular, immunological or neurological illnesses
- Currently pregnant or breast-feeding;
- History of radioactivity exposure via prior nuclear medicine studies or occupational exposure in past twelve months
- Metallic objects in the body that are contraindicated for MRI;
- First-degree relative with psychosis or mood disorders
Data sourced from ClinicalTrials.gov (NCT03302416). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.